Korean J Urol.
2003 Jan;44(1):12-16.
The Therapeutic Effect of Monotherapy and Combined Therapy for Androgen Blockade in Patients with Metastatic Prostate Cancer
- Affiliations
-
- 1Department of Urology, College of Medicine, Dongguk University, Gyeongju, Korea. ksleemd@dongguk.ac.kr
Abstract
-
PURPOSE: We evaluated the therapeutic effect of combined androgen blockade (CAB) compared with that of medical, or surgical, castration monotherapy, in the treatment of the metastatic prostate cancer.
MATERIALS AND METHODS
Of 53 patients with metastatic prostate cancer, we compared the overall survival between CAB and monotherapy groups, using a Kaplan-Meier survival curve. We also compared the therapeutic effect of flutamide and bicalutamide in the CAB group.
RESULTS
There were no differences in known prognostic factors between the CAB and monotherapy groups. The mean survival after treatment were 43 months in the CAB group, and 38 months in monotherapy group, with no significant difference (p=0.470). There were also no differences in the survival rates between the flutamide and bicalutamide groups (p=0.158).
CONCLUSIONS
These results implicate that the CAB was no better than medical, or surgical, castration monotherapy in patients with metastatic prostate cancer, and that flutamide or bicalutamide, in CAB, resulted in similar efficacies and tolerabilities.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Therapeutic Effect of Maximal Androgen Blockade in Metastatic Prostate Cancer
- Chemotherapy With Androgen Deprivation for Hormone-Naïve Prostate Cancer
- Long-Lasting Antiandrogen Withdrawal Syndrome in Castration-Resistant Prostate Cancer: Three Cases With Complete Response
- Change of Bone Mineral Density after 1,25(OH)2VitD Therapy In Newly Diagnosed Prostate Cancer Patients Treated with Total Androgen Blockade: The Prospective Study
- Clinical Response of Combined Androgen Blockade in Metastatic Prostate Cancers
